MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential ...

Ecosystem to Advance Global Diagnostic Accessibility and Seeks Partnerships with Global Healthcare Opportunities YONGIN, ...

Dr. Mendez added, “Because Lee Health serves as an educational training environment for medical students, nurses, pharmacists ...

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

Evaluation of Cytochrome P450 2C9, 2C19, and 2D6 Inhibition on the Pharmacokinetics of Aficamten in Healthy Participants (1091-139) Poster Presentation ... and from the National Medical Products ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

As part of our broader growth strategy, IR-MED is actively working toward uplisting to the Nasdaq Stock Exchange, a move that we believe will enhance shareholder value and expand our reach among ...

Q4 2024 Earnings Call Transcript March 11, 2025 Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.67 EPS, expectations were $-0.39. Operator: Good afternoon, and thank you ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...